The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism

被引：2
|
作者：
Hom, Lindsay [1 ]
Sobieraj, Diana M. [2 ]
机构：
[1] Hartford Hosp, Serv Pharm, Hartford, CT 06102 USA
[2] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Storrs, CT 06269 USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 198卷
关键词：
Venous thromboembolism; Anticoagulant; Rivaroxaban; DEEP-VEIN THROMBOSIS; LENGTH-OF-STAY;
D O I：
10.1016/j.ijcard.2015.06.060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [31] Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants
    Uppuluri, Ellen M.
    Burke, Kelly R.
    Haaf, Christina Mactal
    Shapiro, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (02) : 261 - 268
  • [32] Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
    tenCate, JW
    Buller, HR
    Gent, M
    Hirsh, J
    Prins, MH
    Baildon, R
    Lensing, AWA
    Anderson, DR
    vanBeek, EJR
    Fiesinger, JN
    Tijssen, JGP
    vanBarneveld, A
    Eimers, LT
    Graafsma, YP
    Hettiarachchi, R
    Hutten, B
    Redekop, K
    Haley, S
    LIberale, L
    Finch, T
    Whittaker, S
    Wilkinson, L
    Prandoni, P
    Villalta, S
    Girolami, B
    Bagatella, P
    Rossi, L
    Girolami, A
    Piovella, F
    Barone, M
    Beltrametti, C
    Serafini, S
    Siragusa, S
    Ascari, E
    Kovacs, MJ
    Morrow, B
    Kovacs, J
    Kuijer, PMM
    Koopman, MMW
    Jagt, H
    Weitz, J
    Kearon, C
    Biagioni, L
    Haas, S
    Lossner, F
    Spengel, FA
    Berger, M
    Demers, C
    Poulin, J
    vanderMeer, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10): : 657 - 662
  • [33] Efficacy and Safety of Rivaroxaban Versus Low Molecular Weight Heparin for Treating Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
    Shrestha, Abhigan
    Mainali, Nischal
    Shrestha, Sajina
    Jaiswal, Vikash
    Rajak, Kripa
    Edara, Ravi Sankar Reddy
    Anil, K. C.
    CIRCULATION, 2024, 150
  • [34] Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin
    Thomas M. Hyers
    Alex C. Spyropoulos
    Journal of Thrombosis and Thrombolysis, 2007, 24 : 225 - 232
  • [35] Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin
    Hyers, Thomas M.
    Spyropoulos, Alex C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2007, 24 (03) : 225 - 232
  • [36] Evaluation of low molecular weight heparin versus heparin for inpatient treatment of venous thromboembolism.
    Sakaan, Sami
    Hudson, Joanna Q.
    Jones, Angel
    Usery, Justin B.
    PHARMACOTHERAPY, 2012, 32 (10): : E276 - E277
  • [37] Rivaroxaban Versus Low Molecular Weight Heparin For The Prevention Of Venous Thromboembolism After Orthopedic Surgery: A Population-Based Study
    Lazo-Langner, Alejandro
    Fleet, Jamie L.
    McArthur, Eric
    Garg, Amit X.
    BLOOD, 2013, 122 (21)
  • [38] Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma
    Jacobs, Benjamin N.
    Cain-Nielsen, Anne H.
    Jakubus, Jill L.
    Mikhail, Judy N.
    Fath, John J.
    Regenbogen, Scott E.
    Hemmila, Mark R.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 83 (01): : 151 - 158
  • [39] Low-molecular-weight heparin for venous thromboembolism
    Schafer, AI
    HOSPITAL PRACTICE, 1997, 32 (01): : 99 - &
  • [40] Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux
    Welzel, D.
    Hull, R.
    Fareed, J.
    INTERNATIONAL ANGIOLOGY, 2011, 30 (03) : 199 - 211
12345